Chimerix (NASDAQ: CMRX) reported Q1 EPS of ($0.35), in-line with the analyst estimate of ($0.35). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $1.5 million.

• Reports Positive Top-line Survival Data from Pivotal Mouse Study as Key Milestone on Path to Smallpox Regulatory Submission
• Plan to Focus on Execution of Smallpox Program, Halting All Other Brincidofovir Development Activities
• Restructuring to Reduce Workforce by More Than 50%, Maintaining Key Capabilities and Preserving Capital for New Programs

For earnings history and earnings-related data on Chimerix (CMRX) click here.